Q4 Results 13th May Live: Bharti Airtel, TVS Motor, Power Finance, Tata Motors, DLF, Cipla, Oil India, HPCL, NLC India, TVS Holdings to announce Q4 results

Q4 Results Today, 13th May 2026 Live Updates: Find all the latest Q4 results 2026 updates of Abhijit Trading Company, Andhra Cements, Adf Foods, Aeroflex Enterprises, Balaji Amines, The Bombay Burmah Trading Corporation, Bharti Airtel, Bharti Hexacom, Black Rose Industries, Bombay Potteries & Tiles, CARE Ratings, Chemfab Alkalis, Cipla, CL Educate, Concord Control Systems, Crompton Greaves Consumer Electricals, CyberTech Systems and Software, DCM Shriram, DIC India, Digispice Technologies, DLF, eClerx Services, Ester Industries, Euphoria Infotech (India), Expleo Solutions, Flora Corporation, Gallard Steel, GK Energy, GlaxoSmithKline Pharmaceuticals, Gujarat Petrosynthese, Hindustan Petroleum Corporation, Hypersoft Technologies, IEC Education, Inventurus Knowledge Solutions, Interarch Building Solutions, Jayshree Chemicals, Jet Freight Logistics, Jetmall Spices and Masala, JSL Industries, JSW Dulux, Jupiter Infomedia, Kaynes Technology India, Kirloskar Brothers, Laxmi India Finance, LIC Housing Finance, Loyal Equipments, Man Infraconstruction, Mangal Electrical Industries, Metropolis Healthcare, Modi Naturals, Nitco, NLC India, Neopolitan Pizza And Foods, Oil India, OM Infra, Onesource Specialty Pharma, Panth Infinity, Paras Defence and Space Technologies, Perfectpac, Permanent Magnets, Pune E - Stock Broking, Power Finance Corporation, Photoquip India, Progrex Ventures, Pyramid Technoplast, Quality Power Electrical Equipments, Redington, Sodhani Academy of Fintech Enablers, Sagar Systech, Sagar Cements, Sangam Finserv, SecMark Consultancy, Seshachal Technologies, Sharda Cropchem, Sicagen India, Signatureglobal (India), SKF India, Smartlink Holdings, Smruthi Organics, Shree Ram Twistex, Stallion India Fluorochemicals, Starteck Finance, Suditi Industries, Sunshield Chemicals, Suven Life Sciences, SW Investments, Texmaco Infrastructure & Holdings, Tourism Finance Corporation of India, Transwarranty Finance, The Investment Trust Of India, Tube Investments of India, Tata Motors, TVS Holdings, TVS Motor Company, Veefin Solutions, Vega Jewellers, Yash Highvoltage, Zaggle Prepaid Ocean Services, Ardi Investments & Trading Company, and ZF Commercial Vehicle Control Systems India. - May 13, 2026 11:58 Q4 results live: Kaynes Technology India Limited shares rise nearly 2 % - May 13, 2026 11:52 Q4 results live: Ventive Hospitality grows 28% EBITDA jump, PAT hits ₹502 Cr in FY26 Ventive Hospitality Ltd reported strong consolidated performance for Q4 and FY26, with Q4 revenue rising 21 per cent year-on-year to ₹870 crore and PAT surging 72 per cent to ₹259 crore, while full-year revenue grew 24 per cent to ₹2,666 crore and PAT jumped 939 per cent to ₹502 crore from ₹48 crore in FY25 on a proforma basis. Consolidated EBITDA for FY26 increased 28 per cent to ₹1,299 crore, with margins expanding to 49 per cent. The hospitality business posted FY26 revenue of ₹1,980 crore, up 23 per cent YoY, although Q4 performance was partly impacted by geopolitical tensions and travel restrictions. The company also saw strong operational metrics, with Indian hotel ADR rising 13 per cent YoY to ₹12,516 for FY26 and Maldives resorts reporting 15 per cent growth in same-store TRevPAR. During the quarter, Ventive strengthened its portfolio through acquisitions including Sol De Goa, a majority stake in Narmada Estates, and Soho House Mumbai rights, as CEO Ranjit Batra said the company is positioning itself at the intersection of luxury hospitality, lifestyle, and curated living. - May 13, 2026 11:49 Q4 results live: TVS Credit Q4 net profit up 13% at ₹256 crore - May 13, 2026 11:47 Q4 results live: Care Ratings up 1.02% ahead of the results - May 13, 2026 11:05 Q4 results live: Oil India share movement - May 13, 2026 10:58 Q4 results live: Cipla shares in green on results day - May 13, 2026 10:56 Q4 results live: Bharti Airtel Limited shares rise ahead of results - May 13, 2026 10:46 Q4 results update: Analysts' take on Max Financial Citi On Max Financial Recommendation: Buy; Target: ₹2,725, Earlier Target: ₹2,675 Another strong quarter Quarter-on-quarter margin improvement was led by higher operating leverage benefits and likely narrowing of ITC-led drag Positive operating variance provides comfort on back book Persistency trends held up well across buckets Expect growth trajectory to sustain at higher than industry level for private players Investor interest in proposed QIP remains monitorable Valuation remains benign Nomura on Max Fin Buy, TP 2080 Consistent actuarial performance for second year; expect 17% APE/VNB growth in FY27-29F FY26 VNB margins at 25.2%, 110bp beat vs estimate Small positive operating variance (excluding GST and labor law) for second year Protection growth holds; proprietary channel now 45% of total APE mix Distribution reform overhang for sector MOSL on Max Fin Buy TP Rs 1980 Axis Max Life Insurance’s (MAXLIFE) APE grew 18% YoY to INR35.9b (in-line). For FY26, APE grew 20% YoY to INR105b. MAXLIFE’s VNB grew 19% YoY to INR10.1b (4% above est.), resulting in a VNB margin of 28.2% (MOFSLe of 27%) vs 28% in 4QFY25. For FY26, VNB grew 26% YoY to INR26.5b, reflecting a VNB margin of 25.2% (24% in FY25). EV of INR288.7b at the end of FY26 (post-GST and labor code impact of INR3.1b) implies an operating RoEV of 18.7% (19.1% in 12MFY25). Expect VNB margin trajectory to remain stable, as co is likely to reinvest incremental margins arising from product mix shifts into growth opportunities - May 13, 2026 10:45 Q4 results update: Analysts' take on Dixon Kotak Inst Eqt on Dixon Buy, TP Rs 15200 Q4 came in 22% ahead of modest expectation, driven by strong performance in the consumer electronics segment and higher ASP in the mobile segment due to a memory price increase. For FY2027, company has guided for flat volumes (ex-Vivo; ~33 mn) due to weak industry demand and display assembly commissioning by 4QFY27E (two-quarter delay), both of which are negative. On other hand, management indicated that Vivo deal is near closure & mobile PLI 2.0 is likely to be announced soon Lower estimate by 7-13% for FY2027/28E, factoring in a one-quarter lag in the Vivo JV’s contribution and flat smartphone volumes and a delay in entry into display fab. CLSA on Dixon Hold, TP cut to Rs 10,400 from Rs12,100 Dixon’s near‑term earnings are vulnerable to a sustained escalation in global memory prices, while visibility on medium-term growth remains weak as market share in smartphones peaks 4QFY26 results were largely in line with muted expectations, with revenue up 2% YoY and Ebitda down 8% Co has guided for flat smartphone sales YoY (organic) in FY27, which believe is optimistic Over medium term, it expects exports and new growth avenues to sustain momentum Jefferies on Dixon Hold, TP Rs 10,280 vs Rs10,330 Despite 35% fall in 6M, Dixon trades at 51x FY27e PE, above many EMS peers. Mar26-Q EBITDA (in-line with JEFe) declined by -8%YoY. Sales growth decelerated sharply (+2%YoY in H2FY26 vs +53% in H1) dragged by softer consumer sentiment, amid surge in memory prices (affordability hit). Vivo JV PN3 approval awaited. Ex-Vivo, weak outlook for domestic smartphones at 32mn in FY27e (almost flat YoY) HSBC on Dixon Hold TP Rs 12000 4Q results were largely in line with consensus estimates, with mobile phone volumes slightly below expectations With management discussing a multitude of new growth levers, including data centre servers, timely execution is key Cut FY27 EPSe by c4%, mainly from VIVO JV delay; MOSL On Dixon Buy, TP Rs 14600 4Q above estimates, even amid challenging environment. Mobile volumes were hit by weak demand on account of continued high memory prices. Going ahead focus will be on 1) smartphone volume traction as demand has gradually started improving, 2) approval for the Vivo JV, 3) PLI 2.0 with a focus on boosting mobile exports, 4) pace of commissioning of the display facility during 2HFY27, 5) volume improvement in exports Macquarie on Dixon O-P, TP Rs 15000 4Q saw a slight beat, and FY27 commentary was positive. Management expects flattish smartphone volumes in FY27, with revenues aided by 12-15% higher realisation. - May 13, 2026 10:02 Q4 results update: Analysts' take on Dr Reddy’s Morgan Stanley On Dr Reddy’s Maintain Equal-weight; Target Price: ₹1,215 (vs ₹1,259 earlier) Q4 adjusted revenue and EBITDA miss estimates by 2% and 13% respectively Semaglutide ramp-up slightly delayed awaiting Brazil approval Management expects 6-7 mn pen sales in CY26 and 40mn+ capacity in FY28 US business stabilizing post gRevlimid with double-digit FY27 growth guidance Brokerage cuts FY27/FY28 EPS estimates by 3% and 3.5% respectively Execution risks and weak US generics backdrop keep margin outlook subdued Morgan Stanley values DRL at 19x March 2028E P/E Goldman Sachs On Dr Reddy’s Maintain Sell; Target Price: ₹1,050 (vs ₹1,075 earlier) Q4 revenue and EBITDA margin miss estimates amid lower lenalidomide sales One-time shelf stock adjustment impacts profitability Brokerage revises FY27-29 EPS estimates by -9% to +3% Goldman Sachs concerned about overall gOzempic opportunity in Canada Near-to-medium-term pipeline for higher value products remains thin Key base business products facing intense price erosion Citi On Dr Reddy Recommendation: Sell; Target: ₹1,070 Reality check on numbers as gRevlimid tailwinds fade US sales have fallen at pre-gRevlimid levels, indicating erosion in the base-line products Core profitability and US revenues remain under pressure Strong growth in non-US markets appears increasingly cost-funded and dilutive to margins Nomura on DR Reddys Buy, TP Rs 1600 4Q: Adjusted for one-off items, estimate sales were 1% ahead of estimate & EBITDA 3% below estimate Co expects double-digit revenue growth to sustain across all markets excluding NAG. Even in NAG, excluding contribution from gRevlimid in FY26 & likely contribution from Semaglutide in Canada in FY27F, company expects double-digit Growth Company expects gross margin at 50-55% going ahead (vs 48% adjusted gross margin in 4QFY26) and EBITDA margin (including other income) at 20% exSemaglutide Jefferies on DR Reddys U-P, TP Rs 1040 Mar-26Q was weak & missed estimates materially, even after adjusting for multiple one-offs. Margins declined on weak US performance and high SG&A even though India, Russia and Europe delivered growth. Mgt guided for double-digit YoY revenue growth in FY27 ex gRevlimid, in line with expectations. Slower uptake of semaglutide in Canada and delay in launch of Abatacept pose downside risks to our est. - May 13, 2026 09:59 Q4 results live: Abbott India Announces Record ₹656 Dividend MNC pharma giant Abbott India has declared a massive ₹656 per share dividend — one of the highest payouts in the Indian pharma space. Q4 Revenue rises 6.5% YoY to ₹1,709 Cr EBITDA jumps 12.2% YoY to ₹481 Cr EBITDA margin improves by 140 bps Net Profit rises to nearly ₹395 Cr Around 71,000 retail shareholders set to benefit Despite a challenging market environment, Abbott India continues to demonstrate the strength of MNC pharma business models through consistent cash generation, strong margins and shareholder-friendly capital allocation. - May 13, 2026 09:58 Q4 results live: AVADH SUGAR & ENERGY Q4 RESULTS Net Profit: ₹55.61 Cr, down 22.4% YoY, up 233.1% QoQ Revenue: ₹670.61 Cr, down 1.2% YoY, up 5.1% QoQ EBITDA: ₹119.61 Cr, down 19.9% YoY, up 116.0% QoQ Margins: 17.8% vs 22.0% YoY, 17.8% vs 8.7% QoQ - May 13, 2026 09:56 Q4 results live: KAMAT HOTELS Q4 RESULTS Net Profit: ₹16.39 Cr, up 49.2% YoY, down 5.3% QoQ Revenue: ₹110.12 Cr, up 19.2% YoY, down 6.5% QoQ EBITDA: ₹31.91 Cr, up 28.5% YoY, down 18.2% QoQ Margins: 29.0% vs 26.9% YoY, 29.0% vs 33.1% QoQ - May 13, 2026 09:55 Q4 results live: SESHASAYEE PAPER Q4 RESULTS Net Profit: ₹26.05 Cr, down 4.3% YoY, up 39.8% QoQ Revenue: ₹591.84 Cr, up 17.8% YoY, up 53.0% QoQ EBITDA: ₹23.59 Cr, down 6.5% YoY, down 4.5% QoQ Margins: 4.0% vs 5.0% YoY, 4.0% vs 6.4% QoQ - May 13, 2026 09:53 Q4 results live: BOROSIL RENEWABLES Q4 RESULTS NET PROFIT TURNAROUND TO ₹169.14 CR VS LOSS OF ₹20.10 CR (YOY) | UP 69.0% (QOQ) (Tax credit boosted PAT) REVENUE UP 17.8% AT ₹439.92 CR (YOY) | UP 12.7% (QOQ) EBITDA UP 782.5% AT ₹136.38 CR (YOY) | UP 10.8% (QOQ) MARGINS 31.0% VS 4.1% (YOY) | 31.0% VS 31.5% (QOQ) Published on May 13, 2026